Article Information
PMID
Published By
Print ISSN
0250-7005
Online ISSN
1791-7530
History
- Received August 14, 2019
- Revision received September 3, 2019
- Accepted September 18, 2019
- Published online September 30, 2019.
Copyright & Usage
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved
Author Information
- SHOTARO YASUOKA1,2⇑,
- TAKESHI YUASA1,
- MASAHIRO OGAWA1,
- YOSHINOBU KOMAI1,
- NOBORU NUMAO1,
- SHINYA YAMAMOTO1,
- YUKIHIRO KONDO2 and
- JUNJI YONESE1
- 1Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
- 2Department of Urology, Nippon Medical School Hospital, Tokyo, Japan
- Correspondence to: Shotaro Yasuoka, MD, Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan. Tel: +81 335200111, Fax: +81 335200141, e-mail: shotaro.yasuoka{at}jfcr.or.jp
Statistics from Altmetric.com
Cited By...
In this issue
Jump to section
Related Articles
Cited By...
- Risk Factors and Clinical Significance of Grade >=3 Neutropenia During the First Cycle of Cabazitaxel Therapy With Primary Pegfilgrastim Prophylaxis in Metastatic Castration-resistant Prostate Cancer
- Patients Diagnosed With Metastatic Castration-sensitive Prostate Cancer and High Serum Lactate Dehydrogenase Levels Did Not Receive an Adequate Dose of Cabazitaxel
- Sarcopenia and Visceral Metastasis at Cabazitaxel Initiation Predict Prognosis in Patients With Castration-resistant Prostate Cancer Receiving Cabazitaxel Chemotherapy